Abbott , a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) technology ...
Tandem Diabetes Care (NASDAQ:TNDM) reported record fourth-quarter and full-year 2025 results while outlining a major shift in ...
Theranica, a neuromodulation therapeutics company advancing clinically validated, drug-free treatments for idiopathic pain conditions and setting a new standard of care in migraine with REN-based ...
A manufacturing problem in Abbott glucose sensors for diabetes patients has been tied to at least seven deaths and hundreds ...
Saputo Cheese has recalled certain cottage cheese products sold under Walmart's house brand, Great Value, the Food and Drug Administration announced.
For five years, everything went seamlessly, but in November 2025, Newton noticed that Kramer was extremely thirsty, ...
Young and the Invested on MSN
Wall Street loves these 10 dividend aristocrats more than the rest
This article discusses the best dividend aristocrats right now.
I mean there are a number of things which makes us excited going into 2026 as well because this really underpins and gives us the momentum that we were looking for. And I'll start, were we surprised?
Abbott (NYSE:ABT) today announced results from a trial demonstrating better glucose outcomes for users of continuous glucose monitors (CGMs).
Detailed price information for Tandem Diabetes Care (TNDM-Q) from The Globe and Mail including charting and trades.
Proponents say they empower us with personalised insights. Critics call them a waste of money. We test if personal data can help overhaul a healthy person’s diet.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results